How to develop novel treatments for EGFR-mutant lung cancer
Author:
Affiliation:
1. Division of Medical Oncology, Cannizzaro Hospital, Via Messina 829, 95126, Catania, Italy
2. Division of Medical Oncology, University Hospital of Parma, Via Gramsci, 14 43126 Parma, Italy
Publisher
Future Medicine Ltd
Subject
Cancer Research,Oncology,General Medicine
Link
https://www.futuremedicine.com/doi/pdf/10.2217/fon.15.172
Reference17 articles.
1. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
5. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy;Frontiers in Medicine;2019-07-31
2. PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?;Translational Lung Cancer Research;2018-09
3. PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?;Translational Lung Cancer Research;2018-09
4. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection;Critical Reviews in Oncology/Hematology;2018-09
5. Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy;Anticancer Research;2018-05-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3